Relapse or inadequate response in multiple sclerosis: managing the episode and the next treatment decision

New blurred vision, weakness or numbness despite regular medication can make previous treatment feel pointless. The first task is to identify what has changed. A new inflammatory attack, infection-related worsening of old symptoms, sustained progression and another illness require different responses. The description treatment-resistant should also be made specific: does it mean poor recovery from one severe attack, or continuing activity despite an adequately used preventive treatment? That distinction guides the next discussion and avoids treating the label as sufficient reason for an immediate escalation.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

When contacting the team, describe the last stable period, the date symptoms started, whether they persist or fluctuate and what you can no longer do. Mention fever, urinary symptoms, cough, recent infection and medication changes. Relapse assessment generally considers symptoms lasting more than 24 hours, excludes infection or another cause and takes the preceding stable period into account. These are clinical classification criteria; they do not instruct someone with dangerous symptoms to wait before seeking help. NICE recommendations on identifying relapse
A specialist may consider plasma exchange for a severe acute inflammatory demyelinating attack with insufficient recovery after high-dose corticosteroids. The sham-controlled randomised evidence included several inflammatory demyelinating diagnoses. Its response proportion should not be quoted as the guaranteed success rate for an individual with MS. This use concerns a particular acute situation, rather than regular blood cleansing for chronic gradual progression. Original plasma-exchange trial
For some people with highly active relapsing disease despite appropriate disease-modifying therapy, an assessment for autologous haematopoietic stem-cell transplantation may be discussed. The 2025 ECTRIMS and EBMT recommendations address patient selection, the transplant process and continuing risk management. This is not a general cell injection for any persistent symptom, nor a promise to repair established disability. ECTRIMS and EBMT consensus

Quick answer

Full guide

Report the timing and the loss of function

When contacting the team, describe the last stable period, the date symptoms started, whether they persist or fluctuate and what you can no longer do. Mention fever, urinary symptoms, cough, recent infection and medication changes. Relapse assessment generally considers symptoms lasting more than 24 hours, excludes infection or another cause and takes the preceding stable period into account. These are clinical classification criteria; they do not instruct someone with dangerous symptoms to wait before seeking help. NICE recommendations on identifying relapse

Sudden substantial one-sided weakness, speech disturbance, altered awareness or rapid deterioration warrants urgent local assessment. Having MS does not exclude other neurological emergencies. A marked change in vision or mobility also needs prompt contact with a medical service. If a trip to China is being arranged, address the immediate clinical problem first and let the responsible doctors assess whether and how a transfer is appropriate. An existing appointment is not a reason to continue a difficult journey while deteriorating.

Old symptoms may worsen because of a trigger

Infection, fever or increased body temperature can temporarily make previous neurological difficulties more apparent. This is often called a pseudo-relapse. The term does not imply that the problem is imagined; it points toward a different reason for the worsening. Symptoms that do not settle with the trigger, are more severe than before or have a new pattern need reassessment. Relatives should not assume that cooling down resolves every episode. Expert recommendations on relapse assessment

An infection and new inflammatory activity may coexist, so the history and examination matter more than a label chosen at home. For recurrent urinary problems, document recent symptoms and antibiotics to help the team plan investigations. Do not reuse remaining steroids or antimicrobial medicines simply because an earlier episode seemed similar. The treatment target and the monitoring required may be different this time.

Does an MRI have to come before treatment?

A clinically clear relapse does not always require a new MRI before it can be managed. Imaging can be particularly useful when the presentation is uncertain, unusually severe or relevant to an escalation decision. Where contrast imaging is needed, the team should coordinate its timing with corticosteroids because treatment can shorten the period of lesion enhancement. The need for information must be considered alongside the need for timely care. Expert recommendations on MRI during relapse

Tell the receiving hospital exactly when steroids were first and last given, including the medicine and course used. Bring images from before and after treatment where available. Absence of enhancement alone cannot prove that an attack never happened. Conversely, a new lesion should be interpreted with symptoms, treatment exposure and the quality of the earlier comparison scan. Accurate dates help prevent a misleading reading of either result.

What steroids can address, and how they are given

The decision to use corticosteroids depends on the impact of the attack and the person's risks. Not every mild relapse requires a treatment course. Vision, walking, self-care and the ability to carry out usual tasks matter, together with conditions such as diabetes, significant mood symptoms or infection. Recovery should be reviewed after treatment; the final infusion day is not necessarily the final neurological outcome. NICE acute relapse treatment guidance

Intravenous administration is not automatically more effective than an appropriate oral regimen. The COPOUSEP randomised trial compared high-dose oral and intravenous methylprednisolone in selected adults with relapsing-remitting MS and supported non-inferiority for the short-term outcome studied. This was a defined, supervised regimen. It does not support assembling a course from ordinary low-dose tablets or assuming that every severe or medically complicated attack can be treated in the same setting. Original COPOUSEP trial

Before starting, ask whether admission is needed, who will respond to blood-glucose, sleep or mood problems, and when recovery will be assessed. Difficulty eating, limited help at home or a previous significant steroid reaction should be part of the setting decision. The clinician should determine whether further treatment is appropriate. Copying the length of an earlier course can miss changes in both the attack and the patient's health.

Severe attacks with inadequate recovery may need rescue treatment

A specialist may consider plasma exchange for a severe acute inflammatory demyelinating attack with insufficient recovery after high-dose corticosteroids. The sham-controlled randomised evidence included several inflammatory demyelinating diagnoses. Its response proportion should not be quoted as the guaranteed success rate for an individual with MS. This use concerns a particular acute situation, rather than regular blood cleansing for chronic gradual progression. Original plasma-exchange trial

Arrangements involve both the neurological team and a service able to perform and monitor the procedure. Vascular access, circulatory status and other medicines need assessment. Potential issues include hypotension, citrate-related low calcium and access complications. Provide the complete prescription list and recent administration dates so that the team can consider effects on drug exposure. Patients should not independently hold medicines to prepare for a session. Canadian Blood Services guidance on therapeutic apheresis

If timely rescue treatment is already recommended locally, discuss international transfer with that team. An available local service may better meet the immediate need. When transfer to China is required, the receiving department should review the situation and the support needed during transport. A routine outpatient booking is not confirmation that arrangements for a severely affected patient are complete.

Does one attack mean the preventive medicine has failed?

Assessment of treatment response includes when the drug was started, whether it had sufficient time to act and whether the intended exposure was achieved. Missed doses because of adverse effects, unavailable supplies or difficulty injecting require different solutions from activity despite consistent treatment. The clinical and MRI timeline helps the neurologist decide whether to observe further, address practical barriers or change therapy. American Academy of Neurology disease-modifying treatment guideline

A proposal to use a more effective medicine should identify the problem it is expected to solve. If the dominant concern is gradual deterioration without clear new inflammatory activity, counting relapses alone is insufficient. If intolerance is the main issue, administration method and a different adverse-effect profile may be especially relevant. Patients can explain the burden they most need to reduce, such as time away from work, recurrent infections or difficulty managing treatment at home.

Keep the reason for each change understandable in the record. A general note of inadequate response is less informative than the specific relapse, imaging change or adverse effect that prompted the decision. This prevents a future clinician from treating every discontinued medicine as a biological failure. It also gives the patient a clearer account of which options were unsuitable and why.

A switch needs a managed transition

Some medicines are associated with substantial return of disease activity after interruption. The FDA has warned about severe worsening after fingolimod cessation. Plans involving pregnancy, a different treatment or a threatened supply problem therefore need advance discussion. Stopping first and looking for a new service afterwards can leave the transition unmanaged. A necessary cessation can still be arranged by clinicians with an appropriate observation and treatment plan. FDA fingolimod stopping warning

There is no single washout interval suitable for every switch. Drug persistence, overlapping immune effects, infection risk and the likelihood of renewed activity all matter. The ECTRIMS discussion of treatment de-escalation and discontinuation emphasises medication-specific choices and monitoring. Patients need the last planned old dose, required checks, the proposed next step and a contact route if symptoms change. They should not calculate a treatment gap themselves. ECTRIMS recommendations published in 2025

Coordinate the existing prescription with the Chinese service before travel. Acceptance of records for an opinion does not establish that the next drug is in stock or can be prescribed to you. A research listing is not a substitute for a treatment arrangement either. Travel dates should follow the clinical plan, rather than becoming the reason for an unsupported interruption.

An unusual episode deserves a broader reassessment

New neurological symptoms during some immune treatments can also reflect infection. With natalizumab, progressive multifocal leukoencephalopathy is an important serious brain infection to recognise, and its features can overlap with an MS attack. Progressive changes in thinking, communication, vision or limb function should be reported promptly. Repeating steroids independently can delay clarification. EMA product information updated in 2026 retains the need for appropriate assessment and monitoring. EMA information on Tysabri

If the course or imaging repeatedly seems atypical, reconsidering the original diagnosis may be useful before another long-term escalation. NMOSD and MOG-antibody associated disease are distinct from MS, with different treatment implications. Clinical clues determine whether relevant antibody tests are appropriate, and isolated results should not be self-interpreted. A review of the diagnosis is a way to improve the treatment decision, rather than evidence that the person's symptoms were unimportant. NEMOS differential diagnosis recommendations

Further options still require a defined selection process

For some people with highly active relapsing disease despite appropriate disease-modifying therapy, an assessment for autologous haematopoietic stem-cell transplantation may be discussed. The 2025 ECTRIMS and EBMT recommendations address patient selection, the transplant process and continuing risk management. This is not a general cell injection for any persistent symptom, nor a promise to repair established disability. ECTRIMS and EBMT consensus

Before considering transplantation or a study, clarify the diagnosis, objective activity and previous treatment exposure. If seeking an opinion in China, request a specialist assessment of whether an in-person evaluation is worthwhile and confirm the nature of the proposed service. A patient's experience elsewhere cannot establish your eligibility. The ability to complete follow-up after returning home remains part of the decision.

The final handover after an episode should contain its timeline, infection findings, examinations, steroid or exchange records, recovery so far and the next medication plan. Even when recovery is incomplete, the team can specify when to review it and which rehabilitation goals to pursue. Connecting acute treatment with prevention gives the next clinician the information needed to decide whether another change is justified.